Together for Short Lives
Call the Helpline 0808 8088 100

Early and lethal neurodegeneration with myasthenic and myopathic features: A new ALG14-CDG

Journal title
Neurology
Publication year
2017
Author(s)
Schorling, D. C.; Rost, S.; Lefeber, D. J.; Brady, L.; Muller, C. R.; Korinthenberg, R.; Tarnopolsky, M.; Bonnemann, C. G.; Rodenburg, R. J.; Bugiani, M.; Beytia, M.; Kruger, M.; van der Knaap, M.; Kirschner, J.
Pages
657-664
Volume
89
Number
7

OBJECTIVE: To describe the presentation and identify the cause of a new clinical phenotype, characterized by early severe neurodegeneration with myopathic and myasthenic features. METHODS: This case study of 5 patients from 3 families includes clinical phenotype, serial MRI, electrophysiologic testing, muscle biopsy, and full autopsy. Genetic workup included whole exome sequencing and segregation analysis of the likely causal mutation. RESULTS: All 5 patients showed severe muscular hypotonia, progressive cerebral atrophy, and therapy-refractory epilepsy. Three patients had congenital contractures. All patients died during their first year of life. In 2 of our patients, electrophysiologic testing showed abnormal decrement, but treatment with pyridostigmine led only to temporary improvement. Causative mutations in ALG14 were identified in all patients. The mutation c.220 G>A (p.Asp74Asn) was homozygous in 2 patients and heterozygous in the other 3 patients. Additional heterozygous mutations were c.422T>G (p.Val141Gly) and c.326G>A (p.Arg109Gln). In all cases, parents were found to be heterozygous carriers. None of the identified variants has been described previously. CONCLUSIONS: We report a genetic syndrome combining myasthenic features and severe neurodegeneration with therapy-refractory epilepsy. The underlying cause is a glycosylation defect due to mutations in ALG14. These cases broaden the phenotypic spectrum associated with ALG14 congenital disorders of glycosylation as previously only isolated myasthenia has been described.

Research abstracts